SCHEMBL2958672

SCHEMBL2958672

Fc1cc(Cl)ccc1COc1ccc(Cl)cc1I

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 6/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C9 P11712 2/20 0.49
TBXA2R P21731 2/20 0.49
PTGS1 P23219 2/20 0.49
CYP2C19 P33261 2/20 0.49
PTGER3 P43115 2/20 0.49
PTGER2 P43116 2/20 0.49
MEN1 O00255 1/20 0.45
PKM P14618 1/20 0.45
KMT2A Q03164 1/20 0.45
MRGPRX4 Q96LA9 2/20 0.45
MAPK14 Q16539 1/20 0.44
FNTA P49354 1/20 0.43
FNTB P49356 1/20 0.43
HPD P32754 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26908042 0.88 PTGER1 (0.48) PTGER1CYP1A2CYP2C9TBXA2RPTGS1
SCHEMBL28786604 0.84 MAPK14 (0.45) PTGER1CYP1A2CYP2C9TBXA2RPTGS1
SCHEMBL16195702 0.83 MRGPRX4 (0.61) PTGER1CYP1A2CYP2C9TBXA2RPTGS1
SCHEMBL31326201 0.83 PTGER1 (0.45) PTGER1CYP1A2CYP2C9TBXA2RPTGS1
SCHEMBL14785504 0.79 PTGER1 (0.54) PTGER1CYP1A2CYP2C9TBXA2RPTGS1
SCHEMBL14774702 0.79 PTGER1 (0.54) PTGER1CYP1A2CYP2C9TBXA2RPTGS1
SCHEMBL5099851 0.77 SLC6A4 (0.56) PTGER1MRGPRX4MAPK14
SCHEMBL14774805 0.77 PTGER1 (0.52) PTGER1CYP1A2CYP2C9TBXA2RPTGS1
SCHEMBL2958985 0.77 PTGER1 (0.49) PTGER1CYP1A2CYP2C9TBXA2RPTGS1
SCHEMBL24320312 0.76 PTGER1 (0.48) PTGER1CYP1A2CYP2C9TBXA2RPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7759369-B2 Pyridine compounds for the treatment of prostaglandin mediated diseases GLAXO GROUP LIMITED (GB) 2010-07-20 US disclosed
US-7759369-B2 Pyridine compounds for the treatment of prostaglandin mediated diseases GLAXO GROUP LIMITED (GB) 2010-07-20 US disclosed
US-7759369-B2 Pyridine compounds for the treatment of prostaglandin mediated diseases GLAXO GROUP LIMITED (GB) 2010-07-20 US disclosed
US-20100137378-A1 Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases GLAXO GROUP LIMITED (GB) 2010-06-03 US disclosed
US-20100137378-A1 Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases GLAXO GROUP LIMITED (GB) 2010-06-03 US disclosed
US-20100137378-A1 Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases GLAXO GROUP LIMITED (GB) 2010-06-03 US disclosed
EP-2053042-A1 Pyridine compounds for the treatment of prostaglandin mediated diseases Glaxo Group Limited (GB) 2009-04-29 EP disclosed
EP-2053042-A1 Pyridine compounds for the treatment of prostaglandin mediated diseases Glaxo Group Limited (GB) 2009-04-29 EP disclosed
US-20090099177-A1 PYRIDYL COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-04-16 US disclosed
US-20090099177-A1 PYRIDYL COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-04-16 US disclosed
US-20090099177-A1 PYRIDYL COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-04-16 US disclosed
EP-1833795-B1 PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES GLAXO GROUP LTD (GB) 2009-03-04 EP disclosed
EP-1833795-B1 PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES GLAXO GROUP LTD (GB) 2009-03-04 EP disclosed
EP-2013181-A1 PYRIDYL COMPOUNDS Glaxo Group Limited (GB) 2009-01-14 EP disclosed
US-20080249138-A1 Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases MARTIN PAUL GIBLIN GERARD 2008-10-09 US disclosed
US-20080249138-A1 Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases MARTIN PAUL GIBLIN GERARD 2008-10-09 US disclosed
US-20080249138-A1 Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases MARTIN PAUL GIBLIN GERARD 2008-10-09 US disclosed
WO-2007128752-A1 PYRIDYL COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-11-15 WO disclosed
EP-1833795-A1 PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES GLAXO GROUP LIMITED (GB) 2007-09-19 EP disclosed
WO-2006066968-A1 PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES GLAXO GROUP LIMITED (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137378-A1 Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases PTGER1, PTGDR, PTGER2 PTGER1 1/4885CYP1A2 241/4885CYP2C9 122/4885
US-20080249138-A1 Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases PTGER1, PTGDR, PTGER4 PTGER1 1/4885CYP1A2 140/4885CYP2C9 81/4885
US-20090099177-A1 PYRIDYL COMPOUNDS CYP2C19, CYP4F3, C5 PTGER1 180/4885CYP1A2 24/4885CYP2C9 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.